Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor α receptor: Fc fusion protein

Archives of Dermatology

Volumn 137, Issue 7, 2001, Pages 893-899

  Zeltser, Ross ^a   Valle, Laticia ^a   Tanck, Carol ^a   Holyst, Margaret M ^a   Ritchlin, Christopher ^a   Gaspari, Anthony A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HLA DR ANTIGEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INJECTION SITE; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN MANIFESTATION; T LYMPHOCYTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY; DRUG HYPERSENSITIVITY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INCIDENCE; INFLAMMATORY BOWEL DISEASES; INJECTIONS, SUBCUTANEOUS; KERATINOCYTES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SKIN; T-LYMPHOCYTES;

EID: 0034953354     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Etanercept in patients with psoriatic arthritis and psoriasis
2. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
3. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors
4. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage
5. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
6. Long-term and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 FC fusion protein (TNFR:Fc:Enbrel)
7. Long-term safety and efficacy of TNF receptor (p75) fusion protein (TNFR:Fc; Enbrel) in DMARD refractory rheumatoid arthritis (RA)
8. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
9. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
10. Rapid onset of SCCs in patients with rheumatoid arthritis after starting etanercept therapy
11. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses
12. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: A phase I trial
13. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis
14. Etanercept-associated injection-site reactions
15. Phenolphthalein-induced fixed drug eruption: A cutaneous complication of laxative use in a child
16. Fixed drug eruption: An immunohistochemical investigation of the acute and healing phase
17. Interferon-gamma-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules
18. HLA-DR expression on keratinocytes is a common feature of diseased skin
19. HLA-DR-antigen bearing keratinocytes in various dermatologic disorders
20. The role of IFN-gamma in delayed-type hypersensitivity mediated by Th1 clones
21. Lymphocyte recruitment in delayed-type hypersensitivity: The role of IFN-gamma
22. + T cell-mediated delayed hypersensitivity: Implications for allergies, asthma, and autoimmunity
23. Interferon beta-1 b: Latest published results, 1995